AC-203

DRUG3 trials

Sponsors

Twi Biotechnology Inc., TWi Biotechnology, Inc.

Conditions

Generalized Epidermolysis Bullosa SimplexGeneralized Epidermolysis Bullosa Simplex (EBS)Inherited Epidermolysis Bullosa

Phase 2

A Double-blind, Intra-individual Comparison, POC Trial of AC-203 in EB Patients

CompletedNCT03468322

TWi Biotechnology, Inc.Inherited Epidermolysis Bullosa

Start: 2018-10-20End: 2019-04-09Updated: 2019-04-16

An International, Multicenter, Randomized, Double-Blind, Parallel Group, Vehicle-Controlled, Phase 2/3 Study With Open-Label Extension Evaluating the Efficacy and Safety of Diacerein 1% Ointment for the Treatment of Generalized Epidermolysis Bullosa Simplex (EBS)

Active, not recruitingNCT06073132

TWi Biotechnology, Inc.Generalized Epidermolysis Bullosa Simplex

Start: 2024-04-04End: 2027-03-01Target: 80Updated: 2026-07-09

An International, Multicenter, Randomized, Double-Blind, Parallel Group, Vehicle-Controlled, Phase 2/3 Study with Open-Label Extension Evaluating the Efficacy and Safety of Diacerein 1% Ointment for the Treatment of Generalized Epidermolysis Bullosa Simplex (EBS) [EBShield Study]

RecruitingCTIS2023-508818-42-00

Twi Biotechnology Inc.Generalized Epidermolysis Bullosa Simplex (EBS)

Start: 2024-05-21Target: 72Updated: 2025-11-28